Talaris Therapeutics Inc.

NASDAQ: TALS · Real-Time Price · USD
2.72
-0.02 (-0.73%)
At close: Oct 19, 2023, 10:00 PM

Talaris Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a
Cost of Revenue
n/a n/a n/a
Gross Profit
n/a n/a n/a
Operating Income
-89.73M -76.48M -47.51M
Interest Income
n/a 900.00 n/a
Pretax Income
-73.21M -73.89M -47.83M
Net Income
-73.21M -68.73M -48.16M
Selling & General & Admin
22.75M 19.47M 13.26M
Research & Development
66.98M 57.01M 34.24M
Other Expenses
n/a n/a n/a
Operating Expenses
89.73M 76.48M 47.51M
Interest Expense
n/a 2.58M n/a
Selling & Marketing Expenses
n/a n/a n/a
Cost & Expenses
n/a 76.48M 47.51M
Income Tax Expense
n/a -5.17M 326K
Shares Outstanding (Basic)
25.35M 4.12M 2.91M
Shares Outstanding (Diluted)
25.35M 4.12M 2.91M
EPS (Basic)
-2.89 -16.66 -16.53
EPS (Diluted)
-2.89 -16.66 -16.53
EBITDA
-89.73M -74.31M -46.88M
EBIT
n/a -71.31M -48.16M
Depreciation & Amortization
n/a 2.16M 623K